A phase II trial evaluating the efficacy and safety of epirubicin and cyclophosphamide (EC) followed by docetaxel with gemcitabine (DG) (+trastuzumab if HER2-positive) as neoadjuvant chemotherapy for women with large operable or locally advanced breast carcinoma (ANZ 0502 NeoGem)
收藏数据链接：
官方服务：
资源简介：
HeSANDA 1.0.0
HeSANDA 1.0.0
创建时间：
2023-05-31
